Experimental virus therapy takes on drug-resistant lung cancer
NCT ID NCT06125197
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 30 times
Summary
This early-stage trial tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. The treatment combines a specially designed virus (TILT-123) that targets cancer cells with pembrolizumab, an immunotherapy drug. The main goal is to check safety and find the best dose in about 22 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92658, United States
-
UCLA Jonsson Comprehensive Cancer Center
Santa Monica, California, 90404, United States
Conditions
Explore the condition pages connected to this study.